Endometrial cancer, the first “tailor-made” immunotherapy arrives

Dostarlimab, a monoclonal antibody capable of reactivating the body’s ability to defend itself against endometrial cancer in one out of three patients has been approved in Italy. Dostrarlimab works by reactivating the immune system in women with locally advanced or metastatic disease and dMMR / MSI-H cancer.